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Whole-chromosomal instability (W-CIN) – unequal chromosome distribution during cell divi-
sion – is a characteristic feature of a majority of cancer cells distinguishing them from their
normal counterparts. The precise molecular mechanisms that may cause mis-segregation
of chromosomes in tumor cells just recently became more evident. The consequences
of W-CIN are numerous and play a critical role in carcinogenesis. W-CIN mediates evolu-
tion of cancer cell population under selective pressure and can facilitate the accumulation
of genetic changes that promote malignancy. It has both tumor-promoting and tumor-
suppressive effects, and their balance could be beneficial or detrimental for carcinogenesis.
The characterization of W-CIN as a complex multi-layered adaptive phenotype highlights
the intra- and extracellular adaptations to the consequences of genome reshuffling. It also
provides a framework for targeting aggressive chromosomally unstable cancers.
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INTRODUCTION
Most cancers have an abnormal chromosomal content character-
ized by clonal changes in chromosomal structure and number. It
is now known that greater than 90% of solid tumors and 75%
of blood cancers show some degree of genomic disbalances and
are aneuploid (1). In addition, cancer cell populations very often
show non-clonal cell-to-cell chromosomal heterogeneity. This het-
erogeneity is a marker of ongoing chromosomal instability in
cancers – accelerated rates of changes in chromosome structure,
gains and losses of chromosome segments or whole chromosomes.
Whole-chromosomal instability (W-CIN) – unequal chromosome
distribution during cell division – is a characteristic feature of a
majority of cancer cells distinguishing them from their normal
counterparts.
Chromosomal instability contributes to transformation by
altering the dosage of oncogenes and tumor-suppressors. Gain
and loss of chromosomal material in neoplastic cell populations
is considered to be a process of diversification that leads to the
survival of the fittest clones (2, 3). The evolution of cancer cells
from benign tumor to invasive metastasis appears to correlate
with increased aneuploidy and karyotypic complexity (4). Both
aneuploidy and W-CIN have been associated with poor patient
prognosis, metastasis, and resistance to chemotherapeutics (5–14).
Thus, understanding the mechanisms that cause W-CIN as well as
mechanisms that allow W-CIN cells to survive and acquire malig-
nant features,offers an attractive possibility to interfere with tumor
aggressiveness, and enhance the efficiency of cancer therapy.
COMPLEXITY OF CANCER GENOMES
Cancer genomes are rearranged compared to genomes of nor-
mal cells. They display several types of genomic alterations, which
include point or oligobase mutations, structural rearrangements
(deletions, duplications, insertions, inversions, amplifications,
translocations), and whole chromosome copy-number changes
(gains and losses of the whole chromosomes).
The complexity of genomic rearrangements in cancer cells has
long been recognized due to cytogenetic studies of chromoso-
mal content of cancer cells (15). Extensive catalogs of recurrent
abnormalities in a wide range of tumors have been compiled
from cytogenetic studies1,2. These studies revealed that most of
tumors contain structural or numerical chromosomal abnormal-
ities or, most commonly, both of them in different proportions.
The karyotypic complexity of cancer genomes is reflected in the
aneuploidy of cancer cells. Aneuploidy is a state of unbalanced
number of chromosomes or large segments of chromosomes. An
alteration in the number of whole chromosomes is termed whole-
chromosome aneuploidy. Segmental aneuploidy refers to unbal-
anced regions of chromosomes and is a result of non-reciprocal
structural abnormalities.
Extensive studies by chromosomal and array CGH (aCGH)
demonstrating frequent alterations in multiple regions of the
genome, highlighted the complexity of copy-number changes and
the existence of numerous sub-microscopic gains and losses in
cancer genomes (16–18). Patterns of copy-number alterations
(CNAs) have been associated with cancer type and, sometimes,
subtype as well (19). Before the arrival of high-throughput
sequencing techniques many cancer-related genes has been already
discovered through analysis of individual candidate genes located
in the regions of translocations, amplifications, deletions, and
LOH in cancer cells.
Studies of hundreds of tumor samples by aCGH demon-
strated that a large part of a cancer genome is usually affected
by aneuploidy (20). A study of somatic CNAs (SCNAs) by aCGH
in 3,131 cancer samples corresponding to 26 histological types
found 25% of the cancer genome to be affected by whole arm
or whole-chromosome SCNAs, whereas 10% is affected by focal
SCNAs. There is a 2% overlap between both types (18). The
1http://cgap.nci.nih.gov/Chromosomes/Mitelman
2http://www.ncbi.nlm.nih.gov/sky/skyweb.cgi
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investigators observed an average of 24 gains and 18 losses per
cancer genome as well as a mean of 17 and 16% of the genome
gained or deleted, respectively. In many cases, recurrent chromo-
somal aberrations target known oncogenes or tumor-suppressor
genes whose expression levels are altered by the genomic changes.
Perturbations in epigenetic gene regulation that occur in the
absence of any change in DNA sequence also alter expression of
oncogenes and tumor-suppressor genes (21). Interplay between
genetic and epigenetic changes add another level of complexity to
studies of cancer genome alterations.
Due to the recent development of next generation sequencing
(NGS) and other whole-genome screening methods it is possi-
ble to examine the complexity of genomic alterations considering
simultaneously point mutations, structural rearrangements, and
copy-number changes, gene expression, methylation and their
relative contribution into carcinogenesis. For instance, colorectal
cancers showed in the majority of samples (84%) high aneuploidy
and low mutation level; and in a minority of samples (16%), low
aneuploidy and a high mutation level, due to microsatellite insta-
bility (MIN) or POLE aberrations (22). Endometrial carcinomas
displayed a highly aneuploid group with low mutation level (26%)
and two groups with low aneuploidy: one with highly elevated
mutation level (35%; 7% due to POLE aberrations and 28% due
to MIN); and surprisingly, a second group with low mutation
level (39%), suggesting that perhaps another driving force could
be involved (23). CpG island methylation phenotype (CIMP) was
associated mainly with MIN group in endometrial carcinomas and
colorectal cancers (22, 23). Ovarian carcinomas showed low muta-
tion and high aneuploidy levels almost in all samples analyzed by
NGS (24). These data confirmed different patterns of genomic
complexity and instability in different types of cancer; as well
as the existence of mutation-instability-driven and CIN-driven
malignancies.
There is considerable inter-tumor heterogeneity/variability in
the degree to which tumor genomes are aberrant at the chromoso-
mal level. Some tumors have only few chromosomal aberrations
whereas others may contain dozens. The aberration spectrum
differs in tumors that arise in different anatomical sites and in his-
tologically distinct tumors that arise in the same anatomic location
(1, 12, 25).
INTRA-TUMOR HETEROGENEITY
In addition to the inter-tumor heterogeneity of genomic
rearrangements, cancers display intra-tumor heterogeneity – dif-
ferences in genomes between malignant cells within the same
tumor. By the time of diagnosis, many tumors are composed of
heterogeneous populations of tumor cells. In the majority of can-
cers, the intra-tumor heterogeneity is a result of elevated rates
of chromosomal instability and relatively normal rates of point
mutations (26).
Application of aCGH and sequencing techniques to diverse
tumor types revealed complex subclonal architecture in human
cancers (27). The intra-tumor clonal chromosomal heterogeneity
of cancers has been known since the 70s (28). The initial studies
used G-banding and fluorescence in situ hybridization techniques
to uncover different intra-tumoral patterns of structural and
numerical chromosomal aberrations. Intra-tumor heterogeneity
was visualized by the coexistence of cytogenetically related cell
populations (sidelines) that share several common chromosome
anomalies and exhibit unique karyotypic characteristics. Many
observations of intra-tumor heterogeneity of chromosomal aber-
rations in human cancers exist for squamous cell carcinoma of
the skin (29), breast cancers (30–32) gliomas (33), bone and soft-
tissue sarcomas (34), pancreatic cancers (35). For instance, 35%
of breast cancers and 80% of pancreatic cancers had distinct,
but related clones. Moreover, karyotypically unrelated clones were
found in 25% of the breast cancers and in 40% of the pancreatic
cancers. These unrelated clones were usually near-diploid, carried
simple numerical or structural aberrations (sometimes multiple),
and were found together with grossly aneuploid, highly abnor-
mal cell population (35). Tumor polyclonality was “rediscovered”
recently by cancer genome sequencing based on mutation and
chromosomal aberration analysis as well (36).
In addition to clonal chromosomal aberrations cancer cells with
CIN display a vast range of random aberrations due to persist-
ing chromosomal instability. Each cell in a cancer cell population
could be different from the others because of the presence of
non-clonal rearrangements in addition to clonal ones.
The development of single-cell sequencing approaches is
another avenue for aiding in our quantitative understanding of
intra-tumor cell-to-cell heterogeneity. Characterizing the genomic
features of individual cells – rather than a mixed population
of tumor cells – helps in resolving the mixtures of genetically
distinct cells in a bulk tumor. The first study of so-called single-
nucleus sequencing used single nuclei from breast cancers and
performed low-coverage sequencing to characterize intra-tumoral
DNA copy-number variation (36). Since this study was under-
taken,additional studies of single-cell exome sequencing of human
tumors (specifically, clear-cell renal cell carcinoma and a myelo-
proliferative neoplasm) have explored the potential capability of
single-cell genomics (37, 38). High levels of clonal and non-clonal
genomic heterogeneity were observed in these studies.
What became most evident from the high-throughput compre-
hensive interrogations of cancer genomes?
(1) The existence of mutation-driven and CIN-driven cancers
(majority of analyzed samples) was confirmed;
(2) A high level of inter- and intra-tumor mutational and
sub-microscopic structural chromosomal heterogeneity was
observed in many types of cancers in combination with
large-scale chromosomal heterogeneity;
(3) A process that involves massive de novo structural rearrange-
ment called chromothripsis was discovered (39). A key feature
of chromothripsis is the formation through most likely a cat-
aclysmic event of tens to hundreds of locally clustered DNA
rearrangements.
Genomic heterogeneity together with epigenomic plasticity
is translated into phenotypic proteomic heterogeneity of cancer
cell populations. Huge collection of coexisting subclones pro-
vides opportunities for an endless selection process. These find-
ings suggest also that the linear clonal progression model of
cancer evolution, in which cancers progress through single-cell
clone bottlenecks, might be an oversimplification. The genetic
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heterogeneity and the branching evolutionary trajectories evoke
a remarkably Darwinian perspective of the evolution of cancer
cells. Progression to malignant disease frequently involves diversi-
fication and non-linear dynamics of clonal evolution. Metastases
often contain genetic aberrations not found in the primary tumor
or found in a minor side clone (14, 40) and minor clones pro-
vide a reservoir for relapse in one third of multiple myeloma
patients (41). Intra-tumor genetic heterogeneity suggests that the
therapeutic targeting of cancer-initiating cells is a considerable
challenge. It is becoming increasingly evident that intra-tumor
genetic heterogeneity is one of the underlying causes of resis-
tance to systemic therapy (42). The immediate consequence of
the branching progression model should be improved prioritiza-
tion of therapy targets and search for “founder” events. The urgent
need to address the risk of misleading conclusions based on single
biopsies is also apparent (43).
CHROMOSOMAL INSTABILITY AS A TYPE OF GENOMIC
INSTABILITY
Genomic heterogeneity is a consequence of genomic instability
of cancer cells. Genomic instability refers to increased rates of
alterations in the genome during the life cycle of cells.
Based on the scale of genomic changes there are sev-
eral distinct forms of intrinsic genomic instability: nucleotide
instability due to frequent mutations (NIN), MIN, structural
genomic/chromosomal instability (S-CIN), and W-CIN. These
four types of instability are not mutually exclusive, and can coexist
in the same cells, with S- and W-CIN being the most frequently
found in cancer forms of instability. S- and W-CIN overlap, but
for the most part are independent (44).
The focus of this review is W-CIN – increased rates of chromo-
somal mis-segregations relative to normal diploid cells. The term
CIN became widely used since it was introduced by the ground-
breaking work of Lengauer et al. (45), but very often it is used
instead of aneuploidy, or karyotypic complexity, or heterogene-
ity. Actually, CIN means the presence of instability in cancer cells
in the present or in the past, and the main characteristic of CIN
instability is a rate of instability. For instance, S-CIN is equal to a
number of acquired structural rearrangements per cell per divi-
sion. Similarly, W-CIN can be measured by the amount of gained
or lost chromosomes per cell per division. W-CIN, which con-
sists of elevated rates of chromosome mis-segregation, must be
distinguished from aneuploidy, which is a state of abnormal chro-
mosome number. Defining CIN as a process where rates may vary
led to the realization, that ongoing instability represents persis-
tent defects in equal distribution of chromosomal material into
daughter cells during cancer cell propagation (45, 46).
The presence of chromosomal alterations in a tumor does
not necessarily indicate that the instability persists in the tumor.
Detection of structural and numerical chromosomal alterations
and, especially, heterogeneity of these alterations indicate that
instability occurred in the past, but the question of ongoing insta-
bility usually requires additional investigation. The level of W-CIN
cannot be determined by simply scoring of genomic alterations,
but requires scoring of mitotic abnormalities, including lagging
chromosomes and multipolar mitoses, as well as gains and losses
of chromosomes per cell per division (47). On average, W-CIN
colorectal cancer cells mis-segregate a chromosome once in every
one to five cell divisions (45, 48). A wider range of W-CIN rates
was detected in ovarian, lung, melanoma cancer cells: between one
chromosome lost or gained in 20 cell divisions in ovarian cancer
cell lines up to several chromosomes lost or gained per cell divi-
sion in malignant melanoma and lung cancer cell lines [(49) and
unpublished data].
MOLECULAR MECHANISMS PROMOTING W-CIN
The precise molecular mechanisms that may cause CIN in tumor
cells just recently became more evident. Studies aimed at iden-
tifying the mitotic defects that may be responsible for inducing
chromosome mis-segregation in cancer cells (W-CIN) show that
these defects include spindle assembly checkpoint (SAC) dysfunc-
tion, kinetochore attachment errors, mitotic spindle defects, and
other cell division inaccuracies (50–60). There are many mole-
cular defects leading to chromosomal mis-segregation in model
systems, but which of them are present in cancer cells? Large-
scale genome sequencing has revealed very few mutations in genes
that encode proteins involved in chromosome segregation during
mitosis (22, 24, 26, 61), but reiterated that cancer-causing mutated
genes encode proteins involved in cell cycle control and cell sig-
naling pathways responsible for cell growth and death. Formerly,
the persistent mis-segregation of chromosomes in tumor cells has
been largely attributed to errors arising during mitosis that were
not directly linked to the driver mutations in oncogenic signaling
pathways. Emerging data show that CIN and the oncogenic signal-
ing pathways responsible for driving tumor formation are closely
interrelated [reviewed in Ref. (62)].
DEFECTS IN MITOTIC-CHECKPOINT SIGNALING
A weakened mitotic-checkpoint may allow cells to enter anaphase
in the presence of unattached or misaligned chromosomes. An
extensive search for mitotic-checkpoint defects in human cancers
has uncovered very infrequent mutations of mitotic-checkpoint
genes (63) and more frequent altered expression of mitotic-
checkpoints genes BUB1, BUBR1, BUB3, MAD1, MAD2 [reviewed
in Ref. (64)].
Mitotic-checkpoint dysfunction has been extensively studied
in mouse models [reviewed in Ref. (65–67)]. In all cases, mice
with genetically reduced levels of mitotic-checkpoint components
have an increased level of aneuploidy and CIN in mouse embry-
onic fibroblasts (MEFs) and tissues. Partial loss of SAC function
is responsible for causing W-CIN. Evidence in favor of this view
is derived from the high incidence of aneuploidy and tumorige-
nesis in mice engineered to have weakened SAC activity (68, 69).
Moreover, in humans, reduced SAC activity has been observed
in individuals with Mosaic Variegated Aneuploidy (MVA), an
extremely rare disease strongly linked to mutations in SAC compo-
nent BubR1 (70). Although aneuploid animals with reduced levels
of BUB1, BUBR1, BUB3, RAE1, or both RAE1 and NUP98 fail
to display an increase in spontaneous tumorigenesis, these mice
are prone to carcinogen-induced tumors (69, 71–73), suggesting
that aneuploidy does not initiate cancer in these mouse models,
but rather drives tumor formation in cases in which mutations
at oncogenic or tumor-suppressor loci have already increased the
potential for cellular transformation.
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MEROTELIC ATTACHMENT
One kinetochore can attach to microtubules from both poles of the
spindle and form a merotelic attachment. Kinetochores in human
cells bind approximately 25 microtubules and errors in the orien-
tation of kinetochore-microtubules attachments arise through the
stochastic nature of interactions between microtubules and kine-
tochores. If these attachments persist into anaphase then lagging
chromatid pairs might be mis-segregated or excluded from both
daughter cells during cytokinesis. Unlike other mal-orientations,
merotely evades SAC detection (74) since kinetochores attain full
occupancy of microtubules (with improper orientation).
Cancer cells with CIN have excessive rates of formation of
merotelic attachments (52, 53) and diminished capacity to cor-
rect them (48, 75–77). It was shown that relatively minor per-
turbations in kinetochore-microtubule attachment dynamics are
sufficient to disturb attachment stability required for faithful chro-
mosome segregation, and restoration of kinetochore-microtubule
attachment dynamics leads to the suppression of W-CIN (48,
75–77). Persistence of errors in kinetochore-microtubule attach-
ments was revealed by live imaging of cancer cells (48). Direct
measurements show that many W-CIN cancer cells have hyper-
stable kinetochore-microtubule attachments which undermine
their ability to correct errors and leads to high rates of chro-
mosome mis-segregation. Importantly, increasing the detachment
rate of kinetochore-microtubule improves error correction and is
sufficient to restore faithful chromosome segregation in W-CIN
cancer cells (58, 62, 75, 76).
MULTIPLE CENTROSOMES
Cells that possess more than two centrosomes might form mul-
tiple spindle poles during mitosis. If this defect is not corrected
then a multipolar division might occur, resulting in the produc-
tion of highly aneuploid and often non-viable daughter cells.
Increased centrosome number correlates with aneuploidy and it
has been well documented that cancer cells frequently enter mito-
sis with more than two centrosomes leading to multipolar spindles
[reviewed in Ref. (59, 77, 78)]. However, centrosomes in multipo-
lar spindles often cluster into two groups to allow cells to divide
in a bipolar fashion (79–81). Centrosome clustering may increase
the frequency of incorrect kinetochore-microtubule attachments
[such as merotelic attachments (see previous section)]. Extra
centrosomes are therefore capable of driving chromosome mis-
segregation through a mechanism that is independent of mul-
tipolar divisions. Additional support comes from the realization
that transient defects in spindle geometry in cancer cells, such
as those caused by supernumerary centrosomes, elevate the inci-
dence of merotelic attachments, indicating that some cancer cells
with CIN have excessive rates of formation of attachment errors
(52, 53). Thus, extra centrosomes increase the rate of formation
of kinetochore-microtubule attachment errors leading to W-CIN.
COHESION DEFECTS
The integrity of centromeric structure ensures that kinetochores
are positioned in a back-to-back configuration. If sister chro-
matid cohesion is lost prematurely or persists during anaphase,
chromosomes can be mis-segregated. It has been shown that
defects in pericentromeric cohesion undermine the establishment
of proper kinetochore-microtubule attachments (82). The con-
sequence is an increased rate of formation of kinetochore-
microtubule attachment defects that leads to elevated rates of
chromosome mis-segregation.
When genes that have putative functions in guarding against
chromosome mis-segregation were systematically sequenced in a
panel of aneuploid colorectal cancers (63), 10 of the 11 mutations
identified were in genes that directly contribute to sister chromatid
cohesion, indicating that defects in the machinery that controls
sister chromatid cohesion might promote aneuploidy. However,
those studies only explain the cause of W-CIN in a minority of
tumor cells. Consistently, overexpression of separase or securin,
two key regulators that control the loss of chromatid cohesion,
promotes aneuploidy and cellular transformation (83, 84).
ONCOGENE-INDUCED MITOTIC STRESS MODEL
A recently proposed oncogene-induced mitotic stress model
explains how most tumors can become aneuploid in the absence
of mutations in the mitotic-checkpoint genes (85). The expla-
nation is that activated oncogenes affect also the mitotic process
that controls chromosome segregation. Emerging data show that
W-CIN and the oncogenic signaling pathways responsible for dri-
ving tumor formation are closely interrelated, and novel roles for
oncogenes and tumor-suppressor genes in genome stability are
proposed [reviewed in Ref. (62, 86)]. These include genes partic-
ipating in the RB pathway, the APC pathway, the WNT signaling
pathway, the Ras signaling pathway, the TGF-beta signaling path-
way, the NF-kB pathway, integrin signaling and cell adhesion, the
Hippo signaling pathway, and the DNA damage response. Origi-
nally, many of these genes were thought to be tumor-suppressive
or oncogenic solely because of their role in proliferative con-
trol. But the oncogenic signaling pathways seem to play dual
roles: they act as drivers for tumorigenesis and they induce W-
CIN. This connection to W-CIN arises from the disruption of
the careful orchestration of events required for accurate chro-
mosome segregation during mitosis. This entails decreasing the
rate of correction of kinetochore-microtubule attachment errors
and/or increasing the rate of formation of those errors through
extra centrosomes or by disrupting the centromere geometry
(62). The notion that tumor-suppressor genes (and by extension,
oncogenes) combine their known roles in cell cycle progression,
growth and differentiation with the induction of genomic insta-
bility has a substantial body of evidence to support it [reviewed
in Ref. (86)]. Because of the frequency with which they are dis-
rupted in cancer, chromosome instability caused by their dys-
function may be more central to tumorigenesis than previously
thought (62).
Another recent proposition about how W-CIN can arise is
that replication stress causes whole-chromosome mis-segregation
by premitotic events, with structural chromosome abnormali-
ties precipitating chromosome mis-segregation in mitosis (87).
DNA replication stress has been observed across several tumor
types (88), and in the light of recent findings there is a
need to search for the mechanism that could cause whole-
chromosome mis-segregation as a consequence of replication
stress independently of defects of the segregation process in
mitosis.
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CONSEQUENCES OF CIN
ANEUPLOIDY
Aneuploidy is a direct consequence of W-CIN. We distinguish
two types of aneuploidy in cells with W-CIN: random and clonal.
Since chromosomes are mis-segregated during cell divisions this
results in random aneuploidies. When random aneuploidy pro-
vides proliferation advantages and is selected for, it becomes clonal
(selected) aneuploidy.
Clonal aneuploidy could be low-grade, with only one or few
chromosomal disbalances and near-diploid genome, and high-
grade or gross aneuploidy with many clonal chromosomal gains
and losses that produce extremely disbalanced genomes, usually
with elevated ploidy levels as well. Deviation from low-grade ane-
uploidy to high-grade aneuploidy requires overcoming limitations
exerted by the p53 pathway (48). These limitations seem to be
also relevant to the acquisition of ploidy instability and poly-
ploidization of low-grade-aneuploid/near-diploid genome that
allows cells to propagate with very elevated rates of W-CIN,
mainly due to the “buffering” effect of higher chromosome
number (89).
HETEROGENEITY OF KARYOTYPES
Heterogeneity of chromosomal contents of cells in a cell pop-
ulation with W-CIN is another direct consequence of random
unequal distribution of chromosomes during mitosis. The pres-
ence of W-CIN results in wide spectrum of karyotypes with gains
and losses of different chromosomes in different combinations.
We distinguish clonal heterogeneity and cell-to-cell heterogene-
ity. Clonal heterogeneity – a coexistence of several related clones
in a cellular population, is a result of chromosomal instability in
the past with further selection of these clones. Cell-to-cell hetero-
geneity is related to random gains and losses of chromosomes in
cells and is an indicator of the presence of ongoing chromosomal
instability.
Studying phenotypic switching due to changes of chromosomal
content in glioblastoma, Gao et al. (90) came to the conclusion that
chromosomal instability generates genomic diversity in the tumor
cell populations (and therefore transcriptome diversity), to allow
for environment-facilitated clonal expansion. Studies in microor-
ganisms show that heterogeneity in the DNA could be beneficial in
certain circumstances, increasing survival under selection pressure
(91, 92).
W-CIN PROMOTES DNA DAMAGE AND GENOMIC INSTABILITY
It has been shown that chromosome segregation defects can lead
to DNA damage. For example, lagging chromosomes in anaphase
tend to be trapped in the cytokinetic furrow resulting in DNA
double strand breaks (93, 94). Also, lagging chromosomes tend to
form micronuclei in the subsequent G1 phase. The chromosomes
trapped in micronuclei do not replicate on time with the major
nucleus, are prone to having defects in DNA replication which
cause additional genomic instability, and could even be occasion-
ally pulverized in the subsequent mitosis leading to chromothripsis
(95). These results reveal a potentially vicious cycle. Chromosome
segregation errors lead to DNA damage and that damage may pro-
mote further chromosome mis-segregation and other forms of
genomic instability (20). It was suggested that W-CIN promotes
itself because imbalances due to aneuploidy further destabilizes
symmetrical chromosome segregation (96).
Aneuploid yeast strains also exhibited increases in genomic
instability with elevated rates of point mutations, mitotic recombi-
nation, and further loss of whole chromosomes, as well as defective
DNA repair (97).
CELLULAR AND ORGANISMAL RESPONSES TO W-CIN AND
ANEUPLOIDY
Changes in copy-number of a chromosome can lead to pheno-
types associated with copy-number changes of a specific gene or
several genes located on this chromosome, as well as to general
effects due to changes in copy-number of numerous genes. Whole
copy-number chromosomal alterations promoted by CIN come
with certain costs and benefits for the propagation and survival of
the cell. Large-scale changes in DNA copy-number can cause detri-
mental phenotypes due to the cumulative effects of CNAs in many
genes simultaneously (98). First of all, these changes have adverse
effects on fitness. The most illuminating data came from the work
on yeast strains. Torres et al. (92) used a chromosome transfer
strategy and selectable markers to generate aneuploid yeast strains
with a single extra chromosome. The aneuploid yeast prolifer-
ated more slowly than the wild-type cells, demonstrated delay
in the G1 phase of the cell cycle as well as increased sensitivity
to drugs targeting protein synthesis and folding, and metabolic
changes with increased glucose uptake (97). Similar to disomic
yeast strains, trisomic MEFs show signs of energy and proteomic
stress (99, 100).
Lately, stress/slow-growth-related transcriptional signature
present in aneuploid cells was identified for diverse organisms
and was largely independent of the identity of the extra chromo-
some (101). These results demonstrated that random aneuploidies
of different chromosomes and in different organisms impact sim-
ilar cellular pathways and cause a stereotypical antiproliferative
response: genes that were involved in the response to stress were
consistently upregulated, and genes associated with the cell cycle
and cell proliferation were down-regulated in aneuploid cells.
Gene copy-number changes are generally translated into
changes in gene expression (102). Quantitative proteomic analy-
ses in budding yeast and human cells showed that copy-number
changes result in changes in protein production in many cases
(103, 104) with the exception of proteins that are predominantly
components of large protein complexes, presumably, because
unassembled units of such complexes are generally unstable. For
instance, stoichiometry of ribosomal complex is maintained by the
proteolysis of subunits that fail to assemble into the complex (105).
It was proposed, that aneuploidy could lead to proteotoxic stress
due to accumulation of unfolded, misfolded, aggregated proteins
in a cell, and can lead to the activation of ubiquitin-proteasome
and chaperone pathways activation which, in turn, could require
additional energetic resources (106).
Cells with W-CIN, similar to aneuploid, also have prolifera-
tion defects and show signs of cellular stresses (48). In addition,
high level of chromosome mis-segregation cause activation of p53,
which results in G1 arrest and apoptosis (54), whereas lower levels
of chromosome mis-segregation induce a p53-mediated cellular
arrest (107). It was suggested, that chromosome mis-segregation
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leads to lagging chromosomes and anaphase bridges, which
become damaged during cytokinesis and trigger DNA dam-
age response. Therefore intact DNA damage response limits the
development of W-CIN. Effects of W-CIN are summarized in
Table 1.
ADAPTATIONS TO W-CIN AND ANEUPLOIDY
Chromosome mis-segregation compromises the proliferation of
cells, indicating that additional changes in combination with ele-
vated chromosome mis-segregation rates are required to generate
grossly aneuploid cells (48).
How cells can adapt to tolerate detrimental effects of chromo-
somal instability and aneuploidy? Since propagation of diploid
human cells with mis-segregation of chromosomes is limited by
activation of the p53 pathway (54), deletions or mutations of the
p53 gene are required to allow propagation of cells with W-CIN.
This notion fits with the observation, that p53 pathway is one of the
most frequently disrupted pathways in many types of cancer (108).
Loss of p53 allows highly aneuploid cells to proliferate in vitro (54,
94, 107), but it does not directly cause euploid cells to become
aneuploid. This point is further supported by data showing that
knockout of p53 alone does not lead to chromosomal gains/losses
(109), therefore, p53 does not play a causative role in the creation
of instability, but its role is rather permissive/adaptive.
Another adaptive mechanism to mis-segregation of chromo-
somes is a switch to a genome with a higher level of ploidy
that tolerates multiple chromosomal gains and losses (110). For
instance, tetraploid yeast can tolerate almost 1,000-fold increase
in the rate of chromosomal gains and losses without impairment
of the cell cycle progression (111). Diploid yeast strains with an
extra chromosome are far less sensitive to drugs that target protein
synthesis and protein folding than isogenic haploid strains with
the same chromosome gain (92). Similarly, tetraploid mammalian
cells with CIN and aneuploidy have a near-normal growth rate
compared with isogenic diploid cells (52). Among the cancer cell
lines from the NCI-60 panel, the most heterogeneous and chro-
mosomally unstable cell lines have grossly aneuploid karyotypes
in near-tetraploid/near-pentaploid range [(44) and unpublished
data]. In addition, ploidy instability and the presence of major or
side clones with high ploidy levels was detected in the majority of
grossly aneuploid cancer cell lines from this panel (44). Clearly,
there is a connection between high chromosomal instability rates
and polyploidization, pointing to an adaptive role of this process
in acquisition of high rates of W-CIN allowing further selection
of a genome with gross aneuploidy.
Another characteristic feature of W-CIN cancer cells is the
presence of supernumerary centrosomes. The biological conse-
quence of this could be a multipolar spindle, which generally is
antagonistic to cell viability and proliferation. Although centro-
some amplification has been linked to aneuploidy and multipolar
spindles, there is an observation that extra centrosomes usually
cluster together in two groups during mitosis to prevent spin-
dle multipolarity (79–81). This centrosome clustering represents
another mechanism of cellular adaptation to W-CIN-promoting
conditions.
Several adaptive responses to random aneuploidy were dis-
sected from the work on a panel of aneuploid yeast strains with
Table 1 | Defects leading to CIN, effects of CIN, and adaptations to
chromosomal instability.
Defects leading
to W-CIN
Mitotic-checkpoint relaxation
Centrosome overduplication
Cohesion defects
Merotelic attachment
Effects of W-CIN Random aneuploidy
Karyotypic heterogeneity – basis for phenotypic
selection
Loss of heterozygosity
Loss of tumor-suppressors
Gain of oncogenes
Selected, clonal aneuploidy
Slow proliferation
DNA damage, genomic instability
Unfit cells
Proteotoxic stress
Increased energy needs
Occasional changes of genome favorable for cell
survival and proliferation
Adaptations
Cellular Centrosome clustering
Protein-level dosage compensation
Changes in proteasome-mediated protein
degradation pathway
ATM-p53 pathway inactivation
Polyploidy
Tissue/organ/whole
organism
Response to tissue damage, inflammation, tissue
remodeling
different additional chromosomes. Most of these strains grew
slowly, exhibited a delay in G1 phase, of the cell cycle and demon-
strated increased metabolic requirements (92). It was proposed
that aneuploidy-induced stoichiometric imbalances in proteins
might severely stress proteasomes (91, 97). Interestingly, after
aneuploid strains were grown continuously for 14 days, genetic
alterations that improved their proliferative potential were then
identified by whole-genome sequencing, and two strains indepen-
dently acquired loss-of-function mutation of ubiquitin-specific
protease UBP6 (112). Deletion of UBP6 was found to improve the
growth rates of four disomic strains, and quantitative mass spec-
trometry demonstrated that loss of UBP6 led to attenuation of the
level of proteins overproduced due to random aneuploidies (97,
112). Such mutations represent an adaptive response to adverse
effects of random aneuploidies. Since aneuploidy lead to increased
mutational rate and structural genome instability, acquisition of
adaptive changes might be accelerated by aneuploidy-induced
genomic instability (113).
Adaptations to W-CIN might occur not only on a cellular level,
but on tissue and organismal levels as well (114). For instance,
prolonged DNA damages signaling, a consequence of W-CIN,
leads to secretion of inflammatory cytokines. Moreover, as a
result of excessive W-CIN, some cells can trigger inflammatory
response that promotes tumorigenesis (115). Inflammation and
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tissue remodeling can facilitate tumor progression due to the pro-
duction of growth factors, cytokines, chemokines, prostaglandins,
and angiogenic factors, leading to further W-CIN tumor adapta-
tions in the context of a response to a tissue damage physiological
program (116). Table 1 summarizes possible adaptations that
allow cells with W-CIN to survive.
W-CIN, ANEUPLOIDY, AND CANCER: A COMPLEX
RELATIONSHIP
Since first experimental findings showed that chromosome mis-
segregation (W-CIN) and the following aneuploidy can promote
or inhibit tumorigenesis, several approaches have been taken fur-
ther to examine the impact of aneuploidy and W-CIN on tumori-
genesis [reviewed in Ref. (117–120)]. Studying tumorigenic effects
of aneuploidy per se is limited by the existence of only few ane-
uploidies viable in mammals: two constitutional trisomies can
survive infancy in humans, and none can survive embryonic devel-
opment in mouse. Individuals with trisomy 21 have an increased
risk for acute myeloid leukemia, but decreased risk of developing
solid tumors. It seems that Down and Edwards syndromes increase
the risk of developing childhood cancers (120). This increased
risk was explained by chromosome-specific effects, but not by the
impact of random aneuploidy (121). Women with Turner syn-
drome have an increased risk of developing gonadoblastoma and
brain tumors (122). Is chromosomal instability present in cells
from individuals with constitutional trisomies? Using FISH probes
for chromosomes 8, 15, and 18, Reish et al. (123), showed that
elevated number of random aneuploidies is present in the lympho-
cytes of individuals with Down, Edwards, and Patau syndromes, as
well as Turner syndrome. Therefore, existing data suggest that tri-
somic cells from patients from Down, Edwards, Patau, and Turner
syndromes have an elevated level of W-CIN compared to cells from
normal diploid individuals. If elevated cancer susceptibility can be
attributed to W-CIN or specific aneuploidies present in the cells
of these trisomic patients, remains to be elucidated. Involvement
of W-CIN is supported by the fact that the only known human
heritable syndrome with numerical chromosomal instability due
to biallelic loss-of-function mutation in the spindle checkpoint
component BubR1, MVA, clearly predispose to cancer.
To understand the role of W-CIN in tumorigenesis, mouse
models with decreased fidelity of chromosome segregation have
been generated. Such models of W-CIN use genetic alterations that
interfere with either chromosome segregation machinery or with
SAC function. Results of these studies have been summarized in
several reviews (114, 118, 121) and will not be discussed in details
here. The studies using mouse models have shown that W-CIN
may cause or accelerate tumorigenesis more readily in some organs
than in others; and introduction of W-CIN into mouse models
of cancer has tumor-promoting and tumor-suppressive effects.
These studies also show that both weakening and hyperactivating
of SAC is sufficient to promote W-CIN and to induce tumorigen-
esis. Moreover, crossing mice with mutated SAC components into
mice homozygous for p53 deletion, increased tumorigenesis and
decreased survival compared with either mutation alone (107).
Thus, in the absence of p53 that limits the proliferation of chro-
mosomally unstable cells, more aggressive disease is consistently
observed.
CELLULAR FUNCTIONS AND PROCESSES ASSOCIATED WITH
W-CIN IN CANCER CELLS
Relationships between W-CIN and cellular functions of can-
cer cells require further investigation. Specific cellular processes
have been associated with chromosomal heterogeneity in can-
cer cells (124). It has been found, that cell-to-cell heterogene-
ity is a good substitute for W-CIN [(47) and our unpub-
lished data].
Distribution of genes whose expression correlated with the
level of chromosomal heterogeneity indicated that cell commu-
nication and signal transduction, cell adhesion, motility, and
migration, response to wounding and inflammatory response,
negative regulation of cell proliferation, and DNA replication are
the main biological processes associated with the level of hetero-
geneity of chromosomal content in the cancer cells. Moreover,
genes correlated with chromosomal heterogeneity fell into two
groups based on their positive or negative correlation coefficients,
showing a striking difference between them. Genes, whose expres-
sion positively correlated with the higher levels of chromosomal
heterogeneity, fell into GO categories such as cell communi-
cation and signal transduction, including cell surface receptor-
linked signal transduction, cell adhesion, locomotion, motility,
and migration, development, morphogenesis, and differentia-
tion, response to wounding, and inflammatory response. Genes,
whose higher expression negatively correlated with the high lev-
els of chromosomal heterogeneity, fell into totally different GO
categories: cellular metabolism, nucleic acid metabolism, regula-
tion of transcription, DNA replication, response to DNA damage
stimulus, DNA repair, chromosome organization and biogenesis,
DNA packaging, chromatin condensation, unwinding and repli-
cation initiation, and base-excision repair, cell cycle regulation
(124). This pattern of gene signatures is consistent with meta-
pathway “tissue remodeling” (125) for cancer cells with higher
levels of chromosomal heterogeneity; and with meta-pathway
“proliferation” for cancer cells with lower levels of chromosomal
heterogeneity.
The lower expression of genes involved in DNA damage check-
points (CHK1, CHK2, H2AX, RAD21, XRCC5, DDB1) and DNA
replication prevention (BCCIP, BRCA2, CDT1, MCM2-7, cyclin
B2) correlated with higher numerical chromosomal heterogeneity.
The expression levels of genes involved in DNA packaging, chro-
mosome condensation, and kinetochore formation (H3 histone,
H1FX, H2AX, H2AZ, TOP1, RCC1, RCC2, SMARCA5, RCBTB1,
CENPC1, ZWINT) are also relatively down-regulated in cancer
cells with higher levels of chromosomal heterogeneity compared
to cancer cells with a lower levels of heterogeneity.
A collective molecular portrait associated with chromoso-
mal instability in cancer cells includes relative up-regulation of
genes that are associated with increased motility and migration,
epithelial-mesenchymal transition (EMT), and are critical for
tumor invasion and metastasis: RhoC, fibronectin, LOX, TWIST,
SNAI2, EGFR, laminins, integrins, collagens, CDC42 effector pro-
tein (Rho GTPase binding), Rho family GTPase 3, RAB, CXCL2,
TGF-b2, VEGFC, IL-6, IL-8, CTGF, vimentin, N-cadherin, CD44,
BCAR3, protocadherins, MMP2 and MMP14, NOTCH2, SER-
PINE1, 2, and 8, IGFBP3 and 7, TNFAIP3, TNFRSF12A and 19,
PLAUR, and SPARC (124).
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CANCER CHROMOSOMAL INSTABILITY ADAPTIVE
PHENOTYPE
The presence of chromosomal instability in cancer cells produces a
multi-layered phenotype which comprises an increased predispo-
sition to chromosome mis-segregation during mitosis; an aberrant
repair of DNA breaks, and a survival state specifically adapted to
aneuploidy and to the constant reshuffling of the genome (126).
Identifying molecular, cellular, and microenvironmental processes
underlying and promoting this complex W-CIN phenotype will be
a key step toward understanding cancer development in general
and drug resistance in particular.
Following is a summary of the complex effects of W-CIN on
proliferation and survival of cellular populations, and an intro-
duction of a possible model for a cancer multi-layered W-CIN
adaptive phenotype (Figure 1).
Understanding how W-CIN promotes adaptations can be aided
by the concept of Darwinian selection, which depends on cell-to
cell variations with survival of the fittest in a selective environment
(127). Adaptation is a characteristic feature of human neoplasms;
and the ability of tumors to adapt to external pressures comes from
tumor cell chromosomal heterogeneity – a direct consequence
of W-CIN. Besides heterogeneity, another direct consequence of
W-CIN is random aneuploidy. Aneuploidy invokes multiple cel-
lular stresses and is detrimental for proliferation of cells, unless
occasional beneficial changes are acquired. Therefore, an array of
chromosomal gains and losses produced by W-CIN slow tumor
progression due to the detrimental consequences of genomic
disbalances, but eventually can drive tumor progression by accel-
erating the gain of oncogenic and the loss of tumor-suppressor
loci, and promoting acquisition of cellular adaptations to genomic
disbalances.
Since whole-chromosome mis-segregation accelerate further
chromosomal instability, genomic damage, and acquisition of
mutations, cells can occasionally obtain features that are benefi-
cial for proliferation and survival, facilitating tumor progression.
However, the random nature of chromosomal mis-segregation
implies that it can equally promote the loss of beneficial features,
for instance, due to loss of oncogenes or gain of tumor-suppressors
(128). Due to the heterogeneity of cellular phenotypes in a pop-
ulation of cells with W-CIN, the entire range of different cellular
fitness phenotypes could exist in a population. This implies simul-
taneous coexistence of unfit, dying cells as well as better fitted cells
within the population of W-CIN cancer cells. Fitness heterogene-
ity also may have consequences for proliferation and survival of
chromosomally unstable cells because of the response of tissue
microenvironment (Figure 1).
Connection between inflammation and genomic instability has
been already established due to many observations suggesting that
common cellular and molecular mechanisms are active in wounds
and in cancer sites. It was suggested that tumors, in particular, car-
cinomas, activate the latent wound-healing program on the host
but in an exaggerated and prolonged manner (129). Most of the
genes that orchestrate wound-healing process are important reg-
ulators of cancer growth and progression. Chronic inflammation
is associated with an increase in cytokines, chemokines, reactive
oxygen and nitrogen species, that promote genomic instability
(115, 130). In turn, W-CIN may lead to the tumor cells secreting
factors that recruit inflammatory immune cells or promote tissue
remodeling, including tumor angiogenesis (114).
Chromosomal instability is a multi-layered phenotype that
has to be evaluated based on systemic biological approach which
includes not only studies of genome, cell cycle, and genomic evo-
lution of CIN cancer cells, but also evaluations of their cellular
functions and interactions with surrounding cells and tissues.
Existing data suggest that the CIN phenotype is associated with
the following features:
(a) Changes in the cell cycle organization and coordination lead-
ing to random unequal distribution of genetic material in
daughter cells;
(b) Changes in metabolism and cellular functions due to genomic
imbalances and alterations;
(c) Intracellular mechanisms of adaptation to the consequences
of genome reshuffling;
(d) Extracellular mechanisms of adaptation leading to survival
and selection of karyotypically unstable and aneuploid cells as
part of a program of the response to tissue damage with grad-
ual internalization of proliferative and survival signals (116).
TARGETING CIN PHENOTYPE
Both the causes and the consequences of W-CIN, as well as the
adaptive mechanisms alleviating the detrimental consequences,
offer opportunities for therapeutic intervention. For instance,
drugs that induce energy stress or inhibit autophagy or protein
folding have been shown to specifically inhibit proliferation of
trisomic MEFs and aneuploid human cells (99). Similarly, the
adaptations to mitotic defects could be targeted. For example,
drugs that interfere with centrosome clustering mechanisms could
potentially be lethal to tumor cells with multiple centrosomes, but
spare normal cells. A genome-wide RNAi screen in near-tetraploid
Drosophila S2 cells identified a number of genes required for cen-
trosome clustering (131). The classes of genes identified in this
screen enabled the identification of a range of cellular processes
that control organization of multipolar centrosomes: the SAC
components Mad2, BubR1 (human Bub1), CENP-Meta (human
CENP-E) as well as genes involved in cell polarity, actin regulation,
and cell adhesion.
Taking advantage of the tumor-specific phenotype of centroso-
mal clustering, a cell-based screening strategy was used to identify
small molecules that inhibit centrosomal clustering and thus force
tumor cells with supernumerary centrosomes to undergo multipo-
lar mitoses, and subsequently, apoptosis. Screening of a relatively
small but diverse natural product extract library led to the iden-
tification of griseofulvin, which induced multipolar spindles by
inhibition of centrosome coalescence, mitotic arrest, and subse-
quent cell death in tumor cell lines but not in diploid fibroblasts
and keratinocytes with normal centrosome content (132). Follow-
ing this work, 34 griseofulvin analogs were synthesized and tested
as inhibitors of centrosomal clustering (133). The most active
analogs were found with a 25-fold increase of activity compared
to griseofulvin.
There are multiple possibilities for targeting cancer cells based
on the W-CIN phenotype they posses. Interrogation of the
data-rich drug discovery panel of the NCI-60 cancer cell lines, used
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FIGURE 1 | Schematic representation ofW-CIN adaptive phenotype
model. Oncogene-induced mitotic stress promote mitotic-checkpoint
relaxation, overduplication of centrosomes, defects in chromatid cohesion,
and merotelic attachments of microtubules to kinetochores, leading to
persistent chromosome mis-segregation during mitosis – W-CIN. Direct
consequences of W-CIN are mainly disadvantageous for cell proliferation due
to genomic imbalances produced by random aneuploidy, but beneficial for
survival due to heterogeneity of cellular phenotypes. Proliferation of aneuploid
cells is slower than their normal counterparts because cellular fitness is
decreased due to proteomic, energy, and other stresses. At the same time
heterogeneity allows cells to survive in changing microenvironment, and
occasional genomic changes that produce enhanced fitness of phenotypes
can be selected, giving cells proliferative advantages. Indirect consequences
of W-CIN can be both advantageous and disadvantageous for proliferation of
cells, but, again, beneficial for survival. Due to DNA damage and genomic
instability induced by W-CIN, additional random genomic changes occur.
These changes could give cells proliferative advantages or disadvantages, or
be neutral. DNA damage response protects cells from development of CIN,
unless cells acquired defects in the DNA damage checkpoint that allow them
to proceed through cell cycle and avoid apoptosis. Acquisition of defects in
the DNA damage checkpoint can be facilitated by occasional favorable
genomic changes in cells with W-CIN. At the same time, additional
heterogeneity of cellular phenotypes due to genomic instability enhances
chances of cellular population with W-CIN to sample microenvironment and
survive. Due to phenotypic heterogeneity of the fitness of CIN cells, and the
presence of unfit and dying cells in the cell population, microenvironmental
response to tissue damage can contribute to proliferation and survival of
W-CIN cells. For instance, response to tissue damage can provide support for
the proliferation of better fitted W-CIN cells; enhance their chances for
survival and acquisition of new adaptations through genomic/phenotypic
changes. These changes are going to be selected in the microenvironment,
shaped by physiological responses to tissue damage. Adaptive interactions
with microenvironment can provide CIN cells with opportunities for gradual
internalization of proliferative and survival signals. Anticancer drugs also
create selective microenvironments and promote selection of CIN
phenotypes suited to survive applied treatments.Targeting W-CIN cancer cells
requires taking into account multiple layers of W-CIN adaptive phenotype.
Color coding: red – causes of W-CIN; blue – consequences of W-CIN.
by the National Cancer Institute to screen compounds for anti-
cancer activity, provided a list of potential anticancer agents target-
ing aneuploid and chromosomally unstable cancer cells (134–136),
and confirmed that it is possible to discover potential anticancer
agents based on association of their activity with a determinant of
karyotypic state. It identified 13 classes of chemical compounds
that express more growth-inhibitory activity toward cancer cell
lines with more complex and/or unstable karyotypes. These com-
pounds represent a mostly unexplored set of chemical motifs
whose activities correlate with the variability of the cellular kary-
otypes. These results also suggest that the mechanisms of action of
many well-known anticancer agents are most likely not associated
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with aneuploidy and the chromosomally unstable status of can-
cer cells. Compounds identified in this study may target genes or
pathways; however, it is important to recognize that certain agents
may be active against the “state” of complexity or instability itself
rather than against any specific gene product or pathway.
The possible influence of karyotypic complexity and genetic
instability on the response to individual cytotoxic agents has also
been recognized. For example, taxanes seemed to have an increased
activity in tumors with chromosomal stability; and anthracyclines
and platinum agents may target more karyotypically complex
tumors. Based on these data, the need for new combinatorial
strategies that would target CIN has been suggested (137).
Since survival of W-CIN cancer cells requires extracellular
mechanisms of adaptation, genes that are involved in the shut-
down of tissue repair response could represent promising targets
for cancer therapy (129).
CONCLUSION
As discussed above, W-CIN is a widespread feature of many types
of cancer. It has both tumor-promoting and tumor-suppressive
effects, and their balance could be beneficial or detrimental for
carcinogenesis. Chromosomal instability is a multi-layered phe-
notype that has to be evaluated based on systemic biological
approach which includes not only studies of genome, cell cycle,
and genomic evolution of W-CIN cancer cells, but also evaluations
of their cellular functions and interactions with surrounding cells
and tissues. W-CIN mediates evolution of the cancer cell popula-
tion under selective pressure and facilitates further accumulation
of genetic changes that promote malignancy. Due to gross genomic
imbalances, W-CIN induces changes in metabolism and cellular
functions of cancer cells, as well as intracellular adaptations to
the consequences of genome reshuffling. Moreover, CIN could be
accompanied by extracellular mechanisms of adaptation leading
to survival of karyotypically unstable cancer cell population. These
possibilities need to be further explored. The concept of W-CIN
multi-layered phenotype can aid in developing new strategies for
targeting cancer.
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